OncoNexus(@Onco_Nexus):How are oncologists choosing first-line therapy for advanced HCC in an increasingly crowded treatment landscape? Learn more with @TheGutOncLab as Dr. Mark Yarchoan (@MarkYarchoan) joins Dr. Nicholas Hornstein (@GIMedOnc), Dr. Timothy Brown, MD MSCE (@TimothyJBrownMD), and Dr. Udhayvir Singh Grewal MD (@UGrewalMD), to break down the frontline treatment framework for advanced hepatocellular carcinoma, including how patient and disease characteristics influence the choice between today’s leading immunotherapy-based combinations. Watch the full episode on OncoNexus:

OncoNexus

@Onco_Nexus

Oncology Nexus is a real-world oncology insights platform led by multidisciplinary physicians delivering multimedia to an audience of oncology specialists.

加入 June 2025

579 正在关注 164 粉丝

OncoNexus@Onco_Nexus

2026.08.14 18:00

How are oncologists choosing first-line therapy for advanced HCC in an increasingly crowded treatment landscape? Learn more with @TheGutOncLab as Dr. Mark Yarchoan (@MarkYarchoan) joins Dr. Nicholas Hornstein (@GIMedOnc), Dr. Timothy Brown, MD MSCE (@TimothyJBrownMD), and Dr. Udhayvir Singh Grewal MD (@UGrewalMD), to break down the frontline treatment framework for advanced hepatocellular carcinoma, including how patient and disease characteristics influence the choice between today’s leading immunotherapy-based combinations. Watch the full episode on OncoNexus:

显示更多